Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE...

Full description

Bibliographic Details
Main Authors: Roya Behrouzi, Neil A. J. Ryan, Chloe E. Barr, Abigail E. Derbyshire, Y. Louise Wan, Zoe Maskell, Katie Stocking, Philip W. Pemberton, James Bolton, Rhona J. McVey, Emma J. Crosbie
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
he4
endometrial cancer
atypical hyperplasia
biomarker
therapy
response
levonorgestrel-releasing intrauterine system
lng-ius
Online Access:https://www.mdpi.com/2072-6694/12/2/276

Internet

https://www.mdpi.com/2072-6694/12/2/276

Similar Items